CN108484607A - Novel preparation method of tofacitinib citrate - Google Patents

Novel preparation method of tofacitinib citrate Download PDF

Info

Publication number
CN108484607A
CN108484607A CN201810253318.9A CN201810253318A CN108484607A CN 108484607 A CN108484607 A CN 108484607A CN 201810253318 A CN201810253318 A CN 201810253318A CN 108484607 A CN108484607 A CN 108484607A
Authority
CN
China
Prior art keywords
tofacitinib
citrate
tofacitinib citrate
stirring
temperature
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201810253318.9A
Other languages
Chinese (zh)
Inventor
郝志海
崔宁
张允�
王翠翠
仇渡先
宋先显
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shandong Kexing Bioproducts Co ltd
Original Assignee
Shandong Kexing Bioproducts Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shandong Kexing Bioproducts Co ltd filed Critical Shandong Kexing Bioproducts Co ltd
Priority to CN201810253318.9A priority Critical patent/CN108484607A/en
Publication of CN108484607A publication Critical patent/CN108484607A/en
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Abstract

The invention discloses a novel preparation method of tofacitinib citrate, and particularly provides a preparation method of tofacitinib citrate, which comprises the steps of adding a coarse product of a tofacitinib intermediate into a solvent, completely dissolving at a higher temperature, adding medicinal activated carbon and activated alumina, and stirring for adsorption; filtering to remove medicinal active carbon and active alumina, adding a precooled alkaline aqueous solution into the filtrate, cooling to 0-5 ℃ for crystallization, washing and drying to obtain a refined product of the tofacitinib intermediate; and dissolving citric acid monohydrate into an ethanol water solution, adding the tofacitinib intermediate refined product, and crystallizing to obtain the tofacitinib citrate. The method can obviously reduce the pigments and impurities which are difficult to remove in the tofacitinib intermediate crude product, thereby obtaining the high-purity tofacitinib intermediate refined product.

Description

Novel preparation method of tofacitinib citrate
Technical Field
The invention relates to the field of medicines, and in particular relates to a novel preparation method of tofacitinib citrate.
Background
Tofacitinib citrate (Tofacitinib citrate), a Janus kinase inhibitor developed by Pfizer, U.S. a chemical name of 3- { (3R,4R) -4-methyl-3- [ methyl- (7H-pyrrolo [2,3-d ] pyrimidin-4-yl) -piperidin-1-yl ] -3-oxo-propionitrile citrate with the following structural formula:
the united states Food and Drug Administration (FDA) approved the drug for marketing in 2012 for the treatment of moderate to severe active Rheumatoid Arthritis (RA) that is poorly responsive or intolerant to methotrexate treatment.
In the prior art, N-methyl-N- [ (3R,4R) -4-methylpiperidine-3-yl ] -7-H-pyrrolo [2,3-d ] pyrimidine-4-amine is used as a raw material and reacts with a cyanoacetate compound under an alkaline condition to prepare tofacitinib, such as the preparation method reported in the patent document WO2007012953A2, the yield is low (about 60%), the by-product impurities are more, the refining and purifying process is complex, and the cost for obtaining high-purity refined tofacitinib citrate is high. Therefore, the person skilled in the art is working to optimize the process for the preparation of tofacitinib citrate.
Disclosure of Invention
In view of the defects in the prior art, the technical problem to be solved by the invention is to provide a novel preparation process of tofacitinib citrate, and obtain a high-purity tofacitinib citrate refined product at a lower cost.
In order to achieve the above object, a first aspect of the present invention provides a method for preparing tofacitinib citrate, comprising the steps of:
(1) adding the tofacitinib intermediate crude product into a solvent, completely dissolving at a higher temperature, adding medicinal activated carbon and activated alumina, and stirring for adsorption;
(2) filtering to remove medicinal active carbon and active alumina, adding a precooled alkaline aqueous solution into the filtrate, cooling to 0-5 ℃ for crystallization, washing and drying to obtain a refined product of the tofacitinib intermediate;
(3) citric acid (C) monohydrate6H8O7·H2O) is dissolved in an ethanol water solution, then the refined tofacitinib intermediate is added, crystallization is carried out after complete dissolution, and drying is carried out after washing, thus obtaining the tofacitinib citrate.
In another preferred example, in the step (1), the solvent is ethanol.
In another preferable example, in the step (1), the amount of the medicinal activated carbon is 0.5-1.5% of the mass of the tofacitinib intermediate crude product; and/or the using amount of the activated alumina is 0.5-1.5% of the mass of the tofacitinib intermediate crude product.
In another preferable example, in the step (1), after the medicinal activated carbon and the activated alumina are added, stirring and adsorbing are carried out for 0-10 min, then the temperature is reduced to a lower temperature, stirring and adsorbing are carried out for 20-50 min at the lower temperature, then the temperature is increased to a higher temperature, and stirring and adsorbing are carried out continuously for 10-40 min.
In another preferred example, in the step (2), the alkaline aqueous solution is an aqueous sodium bicarbonate solution; preferably, the mass concentration of the sodium bicarbonate aqueous solution is 0.1-1%.
In another preferred example, in the crude product of the tofacitinib intermediate, the HPLC content of the tofacitinib intermediate is less than or equal to 97 percent; preferably 95% or less.
In another preferred example, in the step (3), the volume ratio of ethanol to water in the ethanol aqueous solution is 3: 1 to 3.
In another preferred example, the step (3) includes the following steps:
citric acid (C) monohydrate6H8O7·H2O) dissolving in an ethanol water solution, adding the refined tofacitinib intermediate, heating and refluxing until the refined tofacitinib intermediate is completely dissolved, cooling to 30-40 ℃, adding water precooled to 0-5 ℃ under an ultrasonic condition, wherein the water is added at a high speedThe temperature is 5ml/min, the ultrasonic frequency is 20kHz, and the power is 500-600W/kg of solution (based on the total volume after the addition is finished); and after the water is added, stopping ultrasonic treatment, maintaining the temperature of the solution at 0-5 ℃, and carrying out heat preservation and crystallization.
In another preferred embodiment, the tofacitinib citrate is a crystalline particle.
In another preferred embodiment, said crystalline particles have an X-ray powder diffraction pattern showing characteristic peaks at about 9.89 °, 10.08 °, 12.77 °, 13.48 °, 15.51 °.
In another preferred example, the X-ray powder diffraction pattern of said crystalline particles shows characteristic peaks at about 3.24 °, 5.21 °, 6.72 °, 8.13 °, 9.89 °, 10.08 °, 11.66 °, 12.77 °, 13.48 °, 14.08 °, 15.51 °, 16.32 °, 19.04 °, 20.52 °, 21.83 °, 23.81 °, 24.36 °, 25.27 °, 26.78 °, 27.26 °.
The invention provides a tofacitinib citrate bulk drug, wherein the tofacitinib citrate bulk drug contains tofacitinib citrate crystal particles with HPLC purity of more than or equal to 99%, and the X-ray powder diffraction pattern of the crystal particles shows characteristic peaks at about 9.89 degrees, 10.08 degrees, 12.77 degrees, 13.48 degrees and 15.51 degrees.
In another preferred example, the X-ray powder diffraction pattern of said crystalline particles shows characteristic peaks at about 3.24 °, 5.21 °, 6.72 °, 8.13 °, 9.89 °, 10.08 °, 11.66 °, 12.77 °, 13.48 °, 14.08 °, 15.51 °, 16.32 °, 19.04 °, 20.52 °, 21.83 °, 23.81 °, 24.36 °, 25.27 °, 26.78 °, 27.26 °.
In another preferred embodiment, the tofacitinib citrate is prepared by the method of the first aspect of the invention.
In a third aspect of the invention, the application of the tofacitinib citrate bulk drug in preparing the drug for treating rheumatoid arthritis is provided.
Technical effects
According to the preparation method of tofacitinib citrate, the pigments and impurities which are difficult to remove in the tofacitinib intermediate crude product are adsorbed by using activated carbon and activated alumina, and the pigments and impurities which are difficult to remove in the tofacitinib intermediate crude product can be obviously reduced by matching with a temperature changing step, so that a high-purity tofacitinib intermediate refined product is obtained. The method can be used for efficiently preparing the high-purity tofacitinib citrate crystal particles, and the prepared tofacitinib citrate crystal particles have good fluidity and uniform particle size, and the solubility in water is not reduced while the particle size is increased.
Drawings
FIG. 1 shows a typical synthetic route for tofacitinib intermediates;
FIG. 2 shows an X-ray powder diffraction pattern of tofacitinib citrate crystals;
FIG. 3 shows DSC results;
FIG. 4 shows the HPLC detection pattern in comparative example 1.
Detailed Description
Before the present invention is described, it is to be understood that this invention is not limited to the particular methodology and experimental conditions described, as such methodologies and conditions may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present invention will be limited only by the appended claims.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. As used herein, the term "about" when used in reference to a specifically recited value means that the value may vary by no more than 1% from the recited value. For example, as used herein, the expression "about 100" includes 99 and 101 and all values in between (e.g., 99.1, 99.2, 99.3, 99.4, etc.).
Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are now exemplified.
The invention provides a preparation method of tofacitinib citrate, which comprises the following steps:
(1) adding the tofacitinib intermediate crude product into a solvent, completely dissolving at a higher temperature (such as about 65 ℃), adding medicinal activated carbon and activated alumina, stirring and adsorbing for 0-10 min, then cooling to a lower temperature (such as about 30-40 ℃), stirring and adsorbing for 20-50 min at a lower temperature, then heating to a higher temperature (such as about 65 ℃), and continuing stirring and adsorbing for 10-40 min;
(2) filtering to remove medicinal active carbon and active alumina, adding a precooled alkaline aqueous solution into the filtrate, cooling to 0-5 ℃ for crystallization, washing and drying to obtain a refined product of the tofacitinib intermediate;
(3) citric acid (C) monohydrate6H8O7·H2O) dissolving in an ethanol water solution, adding the refined tofacitinib intermediate, heating and refluxing to completely dissolve, cooling to 30-40 ℃, adding water precooled to 0-5 ℃ under an ultrasonic condition, wherein the water adding speed is 5ml/min, the ultrasonic frequency is 20kHz, and the power is 500-600W/kg of solution (based on the total volume after the addition is finished); and after the water is added, stopping ultrasound, maintaining the temperature of the solution at 0-5 ℃, preserving heat, crystallizing, washing and drying to obtain the tofacitinib citrate crystal particles.
A typical synthetic route for the crude tofacitinib intermediate is shown in FIG. 1, and is also commercially available from commercial sources, and its HPLC detection method is a conventional method known in the art.
The refining method of tofacitinib citrate provided by the invention is simple to operate, good in batch-to-batch stability and high in yield, and the complex operation of repeated crystallization is avoided by adsorbing the pigments and impurities which are difficult to remove in the tofacitinib intermediate crude product by using activated carbon and activated alumina.
In the research of the inventor, experiments are carried out on various adsorbing materials such as activated carbon, molecular sieves and the like, and the inventors have surprisingly found that pigments and impurities which are difficult to remove in the Tofacitinib intermediate crude product are adsorbed by using the activated carbon and the activated alumina, and further found through repeated experiments that the pigments and the impurities in the Tofacitinib intermediate crude product can be more thoroughly removed by matching with a temperature changing step, and further a high-purity Tofacitinib intermediate refined product can be obtained. In the preparation process, the dosage of the activated alumina is less than 10% of the mass of the crude product of the tofacitinib intermediate, and the yield of the target substance is obviously reduced when the dosage is too large.
In addition, in the salt forming crystallization process, specific ultrasonic conditions are introduced, so that high-purity tofacitinib citrate crystal particles with large particle size can be efficiently prepared, the prepared tofacitinib citrate crystal particles are good in flowability and uniform in particle size, direct tabletting can be carried out, the solubility in water is not reduced while the particle size is increased, and an accelerated test shows that the tofacitinib citrate crystal particles prepared by the method are more stable than tofacitinib citrate crystal particles prepared by a conventional method.
The present invention will be described in further detail with reference to the following examples. It should be understood that these examples are for illustrative purposes only and are not intended to limit the scope of the present invention. Experimental procedures in the following examples, where no detailed conditions are indicated, are generally carried out according to conventional conditions, or according to conditions recommended by the manufacturer. Unless otherwise indicated, percentages and parts are by weight. The test materials and reagents used in the following examples are commercially available without specific reference.
Example 1
Adding 2.0kg of the tofacitinib intermediate crude product (the HPLC purity is about 92%) into 20L of ethanol, heating to 65 ℃ to completely dissolve the tofacitinib intermediate crude product, adding 200g of medicinal activated carbon and 100g of activated alumina, stirring for 10min, continuously stirring, cooling to 10-15 ℃, maintaining for 30min, heating to 65 ℃, continuously stirring for 30min, and filtering while the product is hot. Adding 50L (mass fraction) of sodium bicarbonate solution into the filtrate, cooling to 0-5 ℃, crystallizing for 6h, filtering, washing with cold water, and drying to obtain the refined product of the tofacitinib intermediate, wherein the yield is 89.4%, and the HPLC purity is 99.61%.
Citric acid (C) monohydrate6H8O7·H2O)7.4g was dissolved in 150ml of an aqueous ethanol solution (volume ratio of ethanol to water 3: 2) then adding 10g of tofacitinib intermediate refined product, heating and refluxing to completely dissolve, cooling to 35 ℃, transferring the solution to an ultrasonic processor, adding 100ml of water precooled to 5 ℃ under the ultrasonic condition, wherein the adding speed is 5ml/min, the ultrasonic frequency is 20kHz, and the power is 500W/kg (so as to obtain the total solution after the addition is finished)Product counting); and after the water is added, stopping ultrasonic treatment, maintaining the temperature of the solution at 0-5 ℃, keeping the temperature for crystallization for 2 hours, filtering, washing with cold water, and drying in vacuum to obtain the tofacitinib citrate refined product, wherein the yield is 92.3%, and the HPLC purity is 99.93%.
An X-ray powder diffraction pattern obtained by measuring the tofacitinib citrate crystal prepared in the above way by using a Cu-K alpha ray is shown in figure 2, and the crystal shows characteristic peaks (expressed by 2 theta +/-0.2 diffraction angle) at 3.24 degrees, 5.21 degrees, 6.72 degrees, 8.13 degrees, 9.89 degrees, 10.08 degrees, 11.66 degrees, 12.77 degrees, 13.48 degrees, 14.08 degrees, 15.51 degrees, 16.32 degrees, 19.04 degrees, 20.52 degrees, 21.83 degrees, 23.81 degrees, 24.36 degrees, 25.27 degrees, 26.78 degrees and 27.26 degrees.
The results of differential thermal analysis (DSC) are shown in FIG. 3, and show an endothermic peak at 212-214 ℃. Therefore, the melting point is determined to be 212 to 214 ℃.
Particle size detection was carried out by Malvern laser diffraction method and the median particle size (D50) was determined to be 58.62. mu.m.
The refined tofacitinib citrate product obtained by the embodiment is a new crystal form shown by an XRPD detection result, has larger crystal granularity and good fluidity, and is very convenient for the subsequent use of raw material medicines. The water solubility is detected within 30 minutes at 35 ℃, and the detection result shows that the water solubility can reach 18.67 mg/ml. The accelerated test is carried out under the conditions that the temperature is 40 +/-2 ℃ and the relative humidity is 75 +/-5%, after the mixture is placed for 6 months, the HPLC purity is 99.87%, impurities with obviously increased content are not observed, the phase is not obviously changed, and the stability is excellent.
Example 2
Adding 1.0kg of the tofacitinib intermediate crude product (the HPLC purity is about 92%) into 15L of ethanol, heating to 65 ℃ to completely dissolve the tofacitinib intermediate crude product, adding 150g of medicinal activated carbon and 100g of activated alumina, stirring for 10min, continuously stirring, cooling to 10-15 ℃, maintaining for 30min, heating to 65 ℃, continuously stirring for 35min, and filtering while the product is hot. Adding 40L (mass fraction) of sodium bicarbonate solution into the filtrate, cooling to 0-5 ℃, crystallizing for 6h, filtering, washing with cold water, and drying to obtain the refined product of the tofacitinib intermediate, wherein the yield is 86.3%, and the HPLC purity is 99.81%.
Citric acid (C) monohydrate6H8O7·H2O)7.4g was dissolved in 200ml of an aqueous ethanol solution (volume ratio of ethanol to water 3: 2) then adding 10g of the tofacitinib intermediate refined product, heating and refluxing to completely dissolve, cooling to 35 ℃, transferring the solution to an ultrasonic processor, adding 120ml of water precooled to 5 ℃ under the ultrasonic condition, wherein the adding speed is 5ml/min, the ultrasonic frequency is 20kHz, and the power is 600W/kg (based on the total volume after the addition is finished); and after the water is added, stopping ultrasonic treatment, maintaining the temperature of the solution at 0-5 ℃, keeping the temperature for crystallization for 2 hours, filtering, washing with cold water, and drying in vacuum to obtain the tofacitinib citrate refined product, wherein the yield is 91.2%, and the HPLC purity is 99.91%.
XRPD detection showed characteristic peaks substantially in accordance with example 1. The differential thermal analysis (DSC) results are consistent with those of example 1. The median particle diameter (D50) was found to be 46.81. mu.m. The water solubility is detected within 30 minutes at 35 ℃, and the detection result shows that the water solubility can reach 18.35 mg/ml. The accelerated test is carried out under the conditions that the temperature is 40 +/-2 ℃ and the relative humidity is 75 +/-5%, after the mixture is placed for 6 months, the HPLC purity is 99.82%, impurities with obviously increased content are not observed, the phase is not obviously changed, and the stability is excellent.
Example 3
Adding 1.0kg of the tofacitinib intermediate crude product (the HPLC purity is about 92%) into 10L of ethanol, heating to dissolve completely, adding 100g of medicinal activated carbon and 150g of activated alumina, stirring for 10min, then continuously stirring, cooling to 10-15 ℃, maintaining for 30min, heating to 65 ℃, continuously stirring for 35min, and filtering while hot. Adding 30L of sodium bicarbonate solution (mass fraction of 0.3%) into the filtrate, cooling to 0-5 ℃, crystallizing for 6h, filtering, washing with cold water, and drying to obtain the refined product of the tofacitinib intermediate, wherein the yield is 74.8%, and the HPLC purity is 99.65%.
Citric acid (C) monohydrate6H8O7·H2O)7.4g was dissolved in 150ml of an aqueous ethanol solution (volume ratio of ethanol to water 1: 1) then adding 10g of tofacitinib intermediate refined product, heating and refluxing to completely dissolve, cooling to 35 ℃, transferring the solution to an ultrasonic processor, adding 100ml of water precooled to 5 ℃ under the ultrasonic condition, wherein the adding speed is 5ml/min, and performing ultra-sonicationThe sound wave frequency is 20kHz, and the power is 500W/kg of solution (based on the total volume after the addition is finished); and after the water is added, stopping ultrasonic treatment, maintaining the temperature of the solution at 0-5 ℃, keeping the temperature for crystallization for 2 hours, filtering, washing with cold water, and drying in vacuum to obtain the tofacitinib citrate refined product, wherein the yield is 88.6%, and the HPLC purity is 99.87%.
XRPD detection showed characteristic peaks substantially in accordance with example 1. The differential thermal analysis (DSC) results are consistent with those of example 1. The median particle diameter (D50) was found to be 42.35. mu.m. The water solubility is detected within 30 minutes at 35 ℃, and the detection result shows that the water solubility can reach 18.14 mg/ml. The accelerated test is carried out under the conditions that the temperature is 40 +/-2 ℃ and the relative humidity is 75 +/-5%, after the mixture is placed for 6 months, the HPLC purity is 99.84%, impurities with obviously increased content are not observed, the phase is not obviously changed, and the stability is excellent.
Comparative example 1
2.0kg of the tofacitinib intermediate crude product (HPLC purity is about 92%) is added into 20L of ethanol, heated to 65 ℃ and dissolved completely, then 200g of medicinal activated carbon is added, stirred for 30min and filtered while hot. Adding 50L (mass fraction) of sodium bicarbonate solution into the filtrate, cooling to 0-5 ℃, crystallizing for 6h, filtering, washing with cold water, and drying to obtain the refined product of the tofacitinib intermediate, wherein the yield is 88.6%, and the HPLC purity is 97.82%.
In the comparative example, no activated alumina adsorbent is used, the obtained refined tofacitinib intermediate product is obviously reddish in color and low in purity, and an HPLC detection result shows that the content of the impurity 1 adjacent to a main peak is still high (an HPLC detection map is shown in figure 4, the content of the impurity 1 is about 1.16 percent), and the refined tofacitinib intermediate product can be used after recrystallization is needed. The content of impurity 1 in the crude tofacitinib intermediate used in the invention was about 1.78% (HPLC), and the HPLC content of impurity 1 in the refined tofacitinib intermediate obtained in example 1 was only 0.16%. Therefore, through comparison, the pigment and the impurities can be obviously removed by adsorbing the pigment and the impurities by using the medicinal activated carbon and the activated alumina, so that a high-quality refined product of the tofacitinib intermediate can be obtained.
Comparative example 2
2.0kg of the tofacitinib intermediate crude product (with HPLC purity of about 92%) is added into 20L of ethanol, heated to 65 ℃ and dissolved completely, then 200g of medicinal activated carbon and 100g of activated alumina are added, stirred for 30min and filtered while hot. Adding 50L (mass fraction) of sodium bicarbonate solution into the filtrate, cooling to 0-5 ℃, crystallizing for 6h, filtering, washing with cold water, and drying to obtain the refined product of the tofacitinib intermediate, wherein the yield is 92.3%, and the HPLC purity is 98.35%.
In the comparative example, medicinal activated carbon and activated alumina adsorbent are used for adsorbing pigment and impurities, a temperature change step is not arranged in the middle, the purity of the obtained refined product of the tofacitinib intermediate is obviously lower, and HPLC detection results show that the content of the impurity 1 is still higher (the content of the impurity 1 is about 0.86%), only about 51.7% of the impurity 1 is removed compared with the crude product, and more than 90% of the impurity 1 can be removed in example 1. Therefore, the temperature changing step has obvious influence on impurity adsorption, medicinal activated carbon and activated alumina are used for adsorption, and pigments and impurities can be removed more thoroughly after one-time temperature changing treatment.
Comparative example 3
Citric acid (C) monohydrate6H8O7·H2O)7.4g was dissolved in 150ml of an aqueous ethanol solution (volume ratio of ethanol to water 3: 2) then adding 10g of the refined tofacitinib intermediate product (prepared in example 1), heating and refluxing until the intermediate product is completely dissolved, cooling to 35 ℃, adding 100ml of water precooled to 5 ℃, and adding at the speed of 5 ml/min; after the water is added, maintaining the temperature of the solution at 0-5 ℃, keeping the temperature for crystallization for 2h, filtering, washing with cold water, and drying in vacuum to obtain the tofacitinib citrate refined product with the yield of 86.3% and the HPLC purity of 99.76%.
XRPD detection results show that the characteristic peak is remarkably different from that of example 1, and differential thermal analysis (DSC) results show that the melting point is 202-203 ℃. The median particle diameter (D50) was found to be 11.56 μm. The water solubility was measured at 35 ℃ within 30 minutes and the results showed that the water solubility was only 16.16 mg/ml. The accelerated test was carried out at a temperature of 40 + -2 deg.C and a relative humidity of 75 + -5%, and after standing for 6 months, the HPLC purity was reduced to 99.41%, and two impurities with a content of more than 0.1% appeared.
The foregoing detailed description of the preferred embodiments of the invention has been presented. It should be understood that numerous modifications and variations could be devised by those skilled in the art in light of the present teachings without departing from the inventive concepts. Therefore, the technical solutions available to those skilled in the art through logic analysis, reasoning and limited experiments based on the prior art according to the concept of the present invention should be within the scope of protection defined by the claims.

Claims (10)

1. A preparation method of tofacitinib citrate is characterized by comprising the following steps:
(1) adding the tofacitinib intermediate crude product into a solvent, completely dissolving at a higher temperature, adding medicinal activated carbon and activated alumina, and stirring for adsorption;
(2) filtering to remove medicinal active carbon and active alumina, adding a precooled alkaline aqueous solution into the filtrate, cooling to 0-5 ℃ for crystallization, washing and drying to obtain a refined product of the tofacitinib intermediate;
(3) citric acid (C) monohydrate6H8O7·H2O) is dissolved in an ethanol water solution, then the refined tofacitinib intermediate is added, crystallization is carried out after complete dissolution, and drying is carried out after washing, thus obtaining the tofacitinib citrate.
2. The method of claim 1, wherein in step (1), the solvent is ethanol.
3. The method of claim 1, wherein in the step (1), the amount of the medicinal activated carbon is 10-15% of the mass of the tofacitinib intermediate crude product; and/or the using amount of the activated alumina is 5-15% of the mass of the tofacitinib intermediate crude product.
4. The method according to claim 1, wherein in the step (1), after the medicinal activated carbon and the activated alumina are added, stirring and adsorbing are carried out for 0-10 min, then the temperature is reduced to a lower temperature, stirring and adsorbing are carried out for 20-50 min at the lower temperature, then the temperature is increased to a higher temperature, and stirring and adsorbing are carried out for 10-40 min continuously.
5. The method according to claim 1, wherein in the step (2), the basic aqueous solution is an aqueous sodium bicarbonate solution; preferably, the mass concentration of the sodium bicarbonate aqueous solution is 0.1-1%.
6. The method of claim 1, wherein the HPLC content of the tofacitinib intermediate in the crude tofacitinib intermediate is less than or equal to 97%; preferably 95% or less.
7. The method according to claim 1, wherein in the step (3), the volume ratio of ethanol to water in the ethanol aqueous solution is 3: 1 to 3.
8. The method of claim 1, wherein the tofacitinib citrate is produced as crystalline particles.
9. A tofacitinib citrate bulk drug is characterized in that the tofacitinib citrate bulk drug contains tofacitinib citrate crystal particles with HPLC purity of more than or equal to 99%, and the tofacitinib citrate is prepared by the method of claim 1.
10. The use of tofacitinib citrate bulk drug as claimed in claim 9 for the preparation of a medicament for the treatment of rheumatoid arthritis.
CN201810253318.9A 2018-03-26 2018-03-26 Novel preparation method of tofacitinib citrate Pending CN108484607A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810253318.9A CN108484607A (en) 2018-03-26 2018-03-26 Novel preparation method of tofacitinib citrate

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201810253318.9A CN108484607A (en) 2018-03-26 2018-03-26 Novel preparation method of tofacitinib citrate

Publications (1)

Publication Number Publication Date
CN108484607A true CN108484607A (en) 2018-09-04

Family

ID=63337877

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201810253318.9A Pending CN108484607A (en) 2018-03-26 2018-03-26 Novel preparation method of tofacitinib citrate

Country Status (1)

Country Link
CN (1) CN108484607A (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109516991A (en) * 2018-12-29 2019-03-26 山东罗欣药业集团股份有限公司 A kind of citric acid tropsch imatinib crystal-form compound and preparation method thereof
CN110437234A (en) * 2019-08-07 2019-11-12 广州一品红制药有限公司 Tofacitinib citrate crystal form compound and preparation method and application thereof
CN112430235A (en) * 2019-08-26 2021-03-02 东莞市东阳光仿制药研发有限公司 Preparation method of PF-06651600 intermediate
CN112679508A (en) * 2021-03-09 2021-04-20 正大天晴药业集团南京顺欣制药有限公司 Preparation method of tofacitinib intermediate
CN114685515A (en) * 2022-03-15 2022-07-01 上海蓝乐鸟实业有限公司 Preparation method of tofacitinib

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1596257A (en) * 2001-12-06 2005-03-16 辉瑞产品公司 Novel crystalline compound
CN104530053A (en) * 2014-12-08 2015-04-22 合肥远志医药科技开发有限公司 Preparation method of medicinal crystal form tofacitinib citrate
CN105153166A (en) * 2015-08-07 2015-12-16 湖北丽益医药科技有限公司 N- [ (3R,4R) -1-benzyl-4-methylpiperidin-3-yl ] -N-methyl-7H-pyrrolo [2,3-d ] pyrimidin-4-amine crystal
CN105294698A (en) * 2015-11-30 2016-02-03 山东省药学科学院 Crystalline form of N-methyl-N-((3R,4R)-4-methyl-1-benzyl-3-piperidyl)-7H-pyrrolo[2,3-D]pyrimidine-4-amine
CN105873931A (en) * 2013-10-08 2016-08-17 广东东阳光药业有限公司 Tofacitinib citrate
CN106967072A (en) * 2017-04-12 2017-07-21 山东裕欣药业有限公司 Tofacitinib citrate crystal form compound and preparation method thereof
CN107814802A (en) * 2016-09-12 2018-03-20 江苏艾立康药业股份有限公司 A kind of new method for preparing citric acid tropsch imatinib medicinal crystal-form

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1596257A (en) * 2001-12-06 2005-03-16 辉瑞产品公司 Novel crystalline compound
CN105873931A (en) * 2013-10-08 2016-08-17 广东东阳光药业有限公司 Tofacitinib citrate
CN104530053A (en) * 2014-12-08 2015-04-22 合肥远志医药科技开发有限公司 Preparation method of medicinal crystal form tofacitinib citrate
CN105153166A (en) * 2015-08-07 2015-12-16 湖北丽益医药科技有限公司 N- [ (3R,4R) -1-benzyl-4-methylpiperidin-3-yl ] -N-methyl-7H-pyrrolo [2,3-d ] pyrimidin-4-amine crystal
CN105294698A (en) * 2015-11-30 2016-02-03 山东省药学科学院 Crystalline form of N-methyl-N-((3R,4R)-4-methyl-1-benzyl-3-piperidyl)-7H-pyrrolo[2,3-D]pyrimidine-4-amine
CN107814802A (en) * 2016-09-12 2018-03-20 江苏艾立康药业股份有限公司 A kind of new method for preparing citric acid tropsch imatinib medicinal crystal-form
CN106967072A (en) * 2017-04-12 2017-07-21 山东裕欣药业有限公司 Tofacitinib citrate crystal form compound and preparation method thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
丁绪淮,谈遒编: "《工业结晶》", 31 October 1985 *
赵桂森: "《新药设计与开发基础》", 30 November 2015, 山东大学出版社 *
陈玉昆: "《中药提取生产工艺学》", 31 March 1992 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109516991A (en) * 2018-12-29 2019-03-26 山东罗欣药业集团股份有限公司 A kind of citric acid tropsch imatinib crystal-form compound and preparation method thereof
CN110437234A (en) * 2019-08-07 2019-11-12 广州一品红制药有限公司 Tofacitinib citrate crystal form compound and preparation method and application thereof
CN112430235A (en) * 2019-08-26 2021-03-02 东莞市东阳光仿制药研发有限公司 Preparation method of PF-06651600 intermediate
CN112679508A (en) * 2021-03-09 2021-04-20 正大天晴药业集团南京顺欣制药有限公司 Preparation method of tofacitinib intermediate
CN112679508B (en) * 2021-03-09 2021-08-10 正大天晴药业集团南京顺欣制药有限公司 Preparation method of tofacitinib intermediate
CN114685515A (en) * 2022-03-15 2022-07-01 上海蓝乐鸟实业有限公司 Preparation method of tofacitinib

Similar Documents

Publication Publication Date Title
CN108484607A (en) Novel preparation method of tofacitinib citrate
JP2022003038A (en) Rifaximin
CA2836394A1 (en) Novel ticagrelor co - crystal
JPH0643400B2 (en) A process for the stable transformation of torasemide.
JP6166721B2 (en) 4-tert-Butyl-N- [4-chloro-2- (1-oxy-pyridine-4-carbonyl) -phenyl] -benzenesulfonamide sodium salt polymorph
CN101163704A (en) Tadalafil having a large particle size and a process for preparation thereof
EP1851221A1 (en) Tadalafil having a large particle size and a process for preparation thereof
JP7274000B2 (en) A novel method for producing peramivir trihydrate and its aqueous drying
JP6122002B2 (en) 4-tert-Butyl-N- [4-chloro-2- (1-oxy-pyridine-4-carbonyl) -phenyl] -benzenesulfonamide sodium salt polymorph
CN107011205B (en) A method of producing large-grain occrycetin
JP2014524931A (en) Crystalline form of sodium salt of 4-tert-butyl-N- [4-chloro-2- (1-oxy-pyridine-4-carbonyl) -phenyl] -benzenesulfonamide
CA2861891C (en) Crystal form of (6s)-5-methyltetrahydrofolate salt and method for preparing same
CN107814802A (en) A kind of new method for preparing citric acid tropsch imatinib medicinal crystal-form
JP2004504390A (en) Novel form of (R) -N- [5-methyl-8- (4-methylpiperazin-1-yl) -1,2,3,4-tetrahydro-2-naphthyl] -4-morpholinobenzamide
US7618976B2 (en) Methods for the production of sildenafil base and citrate salt
CN109516991B (en) Tofacitinib citrate crystal form compound and preparation method thereof
CN105153167B (en) A kind of ticagrelor crystallization and the pharmaceutical composition containing the crystallization
CN104817557B (en) A kind of stable crystal form of moxifloxacin hydrochloride and preparation method thereof
CN104725377B (en) A kind of crystal formation of moxifloxacin hydrochloride and preparation method thereof
CN102775407B (en) Stable unformed 5-methyltetrahydrofolate salt and preparation method thereof
CN110343111A (en) Preparation method of tofacitinib citrate
CN104693200B (en) A kind of crystal formation of moxifloxacin hydrochloride and preparation method thereof
EP3981759A1 (en) New crystal form of treprostinil sodium salt and preparation method therefor
EP3342778B1 (en) Crystal form of fludarabine phosphat, preparation method therefor, and application thereof
CN114560895A (en) Preparation method and application of spherical crystal of disodium adenosine triphosphate

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: 250200 2666 Chuang Road, Ming Shui development area, Zhangqiu District, Ji'nan, Shandong.

Applicant after: Kexing biopharmaceutical Co.,Ltd.

Address before: 250200 2666 Chuang Road, Ming Shui development area, Zhangqiu District, Ji'nan, Shandong.

Applicant before: SHANDONG KEXING BIOPRODUCTS Co.,Ltd.

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20180904